Zai Lab's Phase III trial of KarXT for schizophrenia in China showed positive outcomes, meeting primary and secondary endpoints. The trial demonstrated the potential of KarXT as a new treatment option. Zai Lab plans to submit an NDA to NMPA by early 2025.